BOSTON SCIENTIFIC NEUROMODULATION
Manufacturer adverse-event records for BOSTON SCIENTIFIC NEUROMODULATION come from the U.S. Food & Drug Administration (FDA) MAUDE database via openFDA, refreshed March 2026 - see our methodology. Not medical advice.
FDA MAUDE device safety record · 2008–2024 · heavy-book · typical Death-code · injury-heavy
Injury-mix signature
BOSTON SCIENTIFIC NEUROMODULATION leans injury-heavy in event_type mix
Injury-coded event_type share is 90.0% (injury-heavy tercile) beside 0.47% Death-coded (typical). Volume band: heavy.
What the Injury-mix reading shows for BOSTON SCIENTIFIC NEUROMODULATION
The standout signal for BOSTON SCIENTIFIC NEUROMODULATION is Injury-mix: 90.0% Injury-coded (injury-heavy) beside 0.47% Death-coded, on a heavy-book footprint.
As a heavy-book manufacturer, portfolio size and reporting obligations inflate absolute counts - pair BOSTON SCIENTIFIC NEUROMODULATION with device-family pages before treating company totals as a safety verdict. Event_type Death and Injury are one code per report; Patient Outcomes below use a separate FDA population.
Reports span 8 device types, led in this extract by Injury at 55,691 (90.0% of event_type total). Peak single-year volume reaches 6,946 reports across 17 years. These are raw FDA submissions, not adjudicated findings. Snapshot . Verify current communications on the FDA MDR page.
Event Types
Patient Outcomes
FDA patient-outcome codes (separate from event_type). Percentages use this chart's row total.
Devices (8)
Yearly Trend
Read our methodology - how this data is sourced, computed, and verified.